Biopharmaceutical Financialization and Public Funding of Medical Countermeasures (MCMs) in Canada during the COVID-19 Pandemic

Document Type : Original Article


1 Department of Political Science & Public Administration, Middle East Technical University, Ankara, Turkey

2 Department of Political Science, Dalhousie University, Halifax, NS, Canada

3 Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada

4 Health Law Institute, Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

5 Health Law Institute and Technoscience & Regulation Research Unit, Dalhousie University, Halifax, NS, Canada

6 Department of Pediatrics, Department of Sociology, & Social Anthropology, Dalhousie University, Halifax, NS, Canada


Analysing the Canadian government’s efforts to support the development of COVID-19 “medical countermeasures” (MCMs), this article seeks insights into political economy as a driver of pandemic response. We explore whether Canadian public funding policy during the pandemic involved departures from established practices of financialisation in biopharmaceutical research and development, including the dominance of private sector involvement in an IP intensive approach to innovation underscoring profit, and governance opacity.

We interrogate public funding for MCMs by analyzing how much the Government of Canada (GoC) spent, how those funds were allocated, on what terms, and to whom. We identify the funding institutions, and the funds awarded between February 10, 2020, and March 31, 2021, that were allocated to support the research, development, and manufacturing of MCMs, including diagnostics, vaccines, therapeutics, and information about clinical management and virus transmission.  To collect these data, we conducted searches on the Internet, public data repositories, and filed several requests under the Access to Information Act (1985) Subsequently, we carried out a document-based analysis of electronically accessible research contracts, proposals, grant calls, and policy announcements.

Between February 10, 2020 and March 31, 2021, the GoC announced CAD $1.4 billion for research, development and manufacturing of COVID-19 MCMs. Fully 68% (CAD $ 959 million) of the announced public funding was channelled to investment in private sector firms. Canadian public funding showed a consistent focus on early and late stage development of COVID-19 MCMs and the expansion of biopharmaceutical manufacturing capacity. Assessing whether Canada’s investments in to developing COVID-19 MCMs safeguard affordable and transparent access to the products of publicly funded research, we found that access policies on intellectual property management, sharing of clinical data, affordability and availability were not systematic, consistent, or transparent, and few, if any, mechanisms ensured long-term sustainability.

Beyond incremental change in policy goals, such as public investment in domestic biomanufacturing, the features of Canadian public policies endorsing financialization in the biopharmaceutical sector remained largely unchanged during the pandemic.


  1. Cox, R.W., Production Power and World Order: Social Forces in the Making of History. 1987, New York: Columbia University. 500.
  2. Gaskins, R., Equity in Compensation: The Case of Swine Flu, in The Hastings Center Report. 1980. p. 5-8.
  3. O’Connor, J., US Social Welfare Policy: The Reagan Record and Legacy Journal of Social Policy, 1998. 27(1): p. 37-61.
  4. Maldonado, K., L., G, H Moreno COVID-19 and the Hyper-Crisis of Neoliberalism: The Breakdown of Financialization. BRIq, 2020. Volume 1(Issue 3).
  5. Sell, K.S., What COVID19 Reveals About TwentyFirst Century Capitalism: Adversity and Opportunity, . Development, , 2020.
  6. Lazonick, W., and M. Hopkins. , . How Maximizing Share- holder Value Minimized the Strategic National Stockpile: The $5.3 Trillion Question for Pandemic Preparedness Raised by the Ventilator Fiasco. 2020.
  7. GoC, Consultation Documentation: Biomanufacturing in Canada: Considering the Creation of Biomanufacturing Capacity for Canada. 2021,.
  8. Coveri, A., C. Cozza, L. Nascia, A. Zanfei Supply Chain Contagion and the role of industrial policy. Journal of Industrial and Business Economics, 2020. 47: p. 467–482.
  9. Canada, P.H.A.o., Government of Canada's Research Response to COVID. 2020.
  10. Crane, D., It is now permissible to talk about industrial Strategy, in Hill Times. 2021.
  11. “World leaders pledge € 7.4 billion for European Commission’s coronavirus vaccine fundraising conference”, in DW. 2020.
  12. Trudeau, J., S.W Zewde, M. Jae-in, J. Ardern, C. Ramaphosa, P. S. Perez-Castejon, S. Lofven, E. Fakhfakh, The international community must guarantee equal global access to a covid- 19 vaccine, in Washington Post. 2020: as.
  13. WHO, Making the response to COVID-19 a public common good Solidarity Call to Action. 2020
  14. Public Letter by 61 organizations coordinated by Health Action International and European Alliance for Responsible R&D to the members of European Commission and European Parliament MEPs to the European Commission. 2020.
  15. Statutes of Canada 2020 Bill C-13, Section 30 (1.4), Chapter 5, An Act respecting certain measures in response to COVID-19, , First Session, Forty-third Parliament, 68-69 Elizabeth II, 2019-2020, . 2020: March 25, 2020.
  16. Cross S, R.Y., Reddy H, et al. , Who funded the research behind the Oxford–AstraZeneca COVID-19 vaccine? BMJ Global Health, 2021. 6:.
  17. Wouters, J., O. K. Shadlen, M. Salcher-Konrad, A.J.Pollard, H. Larson, Y. Teerawattananon, M. Jit, Challanges in ensuring global acceess to COVID-19 Vaccines: production, affordability, allocation and deployment. Lancet, 2021. 397: p. 1023-34.
  18. Sampatt, B., N., K.Shadlen, The COVID-19 Innovation System. Health Affairs, 2021. 40(3): p. 400-409.
  19. Stein, F., Risky business: COVAX and the financialization of global vaccine equity. Globalization and Health, 2021. 17(1): p. 112.
  20. Epstein G, A., (Ed.) ed. Financialization and the World Economy,. 2005, Edward Elgar.
  21. Davis, F.G.S.K., Financialization of the Economy,. Annual Review of Sociology,, 2015. 41: p. 203-221.
  22. Froud, J., S. & A. Johal, A. Leaver, & K. Williams, Financialisation and Strategy: Narrative and Numbers. 2006, London& NewYork: Routledge: Taylor and Francis Group.
  23. Froud, J., Williams, K. , Private equity and the culture of value extraction. New Political Economy, 2007. 12(3): p. 405-420.
  24. Bryan, D., Martin, R., Rafferty, M.. , Financialisation and Marx: giving labour and capital a financial makeover. Review of Radical Political Economy, 2009. 41(4): p. 458-472.
  25. Gouzoulis, G., G. Galanis, The Impact of Financialisation on public health in times of COVID-19 and beyond. Sociology of Health and Illness, 2021. 43: p. 1328-1334.
  26. Eren Vural, I., Financialisation in health care: An analysis of private equity fund investments in Turkey. Soc Sci Med, 2017. 187: p. 276-286.
  27. Harvey, D., “Neoliberalism as Creative Destruction” The Annals of the American Academy of Political and Social Science, 2007. 610(21).
  28. Eren Vural, I., Domestic Contours of Global Regulation: Understanding the Policy Changes on Pharmaceutical Patents in India and Turkey. Review of International Political Economy, 2007. 14(1).
  29. Sell, K., S. . , Private Power, Public Law: The Globalization of Intellectual Property Rights. 2003, Cambridge, UK:: Cambridge University Press.
  30. May, C., The Denial of History: Reification, intellectual property rights, and the lessons of the past. Capital & Class, 2006. 30(1).
  31. Linsi, L., Speeding up Slowbalization: Global Value Chains after COVID-19, in Malcolm Campbell-Verduy, in The Covid-19 Pandemic: Continuity and Change in the International Political Economy,, S.M. Lukas Linsi, Gerda van Roozendaal, Clara Egger, Greg Fuller, Nadine Voelkner, Editor. 2021, University of Groningen.
  32. Guttman, R., Financialization revisited:the rise and fall of finance-led capitalism. Economia e Sociedade, 2017.
  33. Hall, P.A., Soskice, David (eds.) Varieties of Capitalism. The Institutional Foundations of Comparative Advantage. 2001, Oxford: Oxford University Press.
  34. Gleadle, P., S. Parris, A. Shipman, R. Simonetti Restructuring and innovation in pharmaceuticals and biotechs: The impact of financialisation. Critical Perspectives on Accounting, 2014. 25: p. 67-77.
  35. Lazonick, W., and O. Tulum US Biopharmaceutical finance and sustainability of the biotech business model. Research Policy, 2011. 40: p. 1170-1187.
  36. Light, D., J.Lexchin  Pharmaceutical R&D What do we get for all that money? BMJ,, 2012. 345: p. 22-25.
  37. De Medeiros, C.A., and Nicholas Trebat, Inequality and Income Distribution in Global Value Chains. Journal of Economic Issues, 2017. 51(2): p. 401-408.
  38. Durand, C.a.W.M., Intellectual Monopoly in Global Value Chains, in Working Paper 07/2018. 2018, Department of Economics. The New School for Social Research.
  39. Birch, K., Rethinking Value in the Bio-economy: Finance, Assetization, and the Management of Value, Science,. Technology, & Human Values, 2017. 42(3): p. 460-490
  40. Rutty, C., Personality, Politics and Public Health: The Origins of Connaught Medical Research Laboratories, 1888-1917,, in Figuring the Social: Essays in Honour of Michael Bliss, A.L. E.A. Heaman, Shelley McKellar (eds.), Editor. 2008, University of Toronto Press: Toronto. p. p. 273-303.
  41. Pisano, G., Science Business: The Promise, Reality and the Future of Biotech. 2006., Boston: MA Harvard Business Press.
  42. Tucker, J., J. Chakma, P. W.M.Fedak, M. Cimini , , Catalyzing Capital for Canada’s life Sciences industry. Journal of Commercial Biotechnology, 2011. 17: p. 330-348.
  43. Remillard, R., Government Intervention in Venture Capital in Canada: Toward Greater Transparency and Accountability,. 2017, CD Howe Institute.
  44. Herder, M., The Rhetoric of Innovation. 2006, (LLM Thesis, Dalhousie University, [unpublished].
  45. GoC. Venture Capital in the Canadian Life Sciences Industry. 2017 [cited 2020 May 10,]; Available from:, .
  46. GoC, Federal Budget 2017, Building a Strong Middle Class,. p. 87.
  47. Capital, B., Canada’s Venture Capital Landscape: Challenges and Opportunities. 2017.
  48. Canadian Venture Capital and Private Equity Association (CVCA) , a., Venture Capital Canadian Market Overview, 2020 Year in Review,.
  49. Glenna, L.S., S. Brandl, B. , Neoliberalism, the University, Public Goods, and Agricultural Innovation. Sociologia Ruralis,. 55(4): p. 438-59.
  50. Graham, E., J. , , Ebola vaccine innovation: a case study of pseudoscapes in global health, . Critical Public Health, 2019. 29(4): p. 401-412.
  51. Baksi, S., Epidemics and Capitalism, Accurate Identification of Contradictions,. Economic and Political Weekly, 2020. Vol. 55(18).
  52. Robinson, M., D. , The Market in Mind: How financialization is shaping Neuroscience, Translational Medicine, and Innovation in Biotechnology. 2019: MIT Press.
  53. Downie, J.M.H., Reflections on the Commercialization of Research conducted in public Institutions in Canada. McGill Health Law Publication, 2007. 1(1): p. 23-44.
  54. Tao, C.M.V., Public money, private profit: A history of U of Tʼs MaRS Discovery District - Academic Matters, 2021.
  55. Cordilha, A.C., Public health systems in the age of financialization: lessons from the French case. Review of Social Economy, 2021.
  56. Eren Vural I, H.M., Graham JE. , From sandbox to pandemic: Agile reform of Canadian drug regulation. Health Policy, 2021. 125(9): p. 1115-1120.
  57. Edmonds, S., et al., Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. Journal of Law and the Biosciences, 2020. 7(1).
  58. Fierlbeck, K., J. Graham, M. Herder, ed. Transparency, Power and Influence in the Pharmaceutical Industry: Policy Gain or Confidence Game. 2021, Toronto University Press: Toronto
  59. Cleary, G., E. M, J. Jackson, and F. D. Ledley, Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019. 2021, Institute for new Economic Thinking.
  60. Cueni, T., “The Risk in Suspending Vaccine Patent Rules”, in The New York Times. 2020.
  61. M.Walsh, J.G., Canada will get COVID-19 vaccines after other countries due to lack of manufacturing capacity Trudeau says, in Globe & Mail. 2020.
  62. Lexchin, J., The Roots of Canada’ss COVID-19 Vaccine shortage go back decades. The Conversattion, 2021.
  63. Taylor-Vaisey, N., Canada's COVID-19 vaccine plan What went right and then so wrong. Maclean’s, 2021.
  64. Duke, G.H.a.I.C., Launch & Scale Speedo Meter 2021 Tracking COVID-19 Vaccine Purchases Across the Globe. 2021.
  65. WHO, Operationalising the COVID-19 Technology and Access Pool (C-TAP): A Concept Paper. 2020.
  66. Habibi, R.J.L. COVID-19 Vaccine Race. Open Canada 2021 March 9th, 2021; Available from:
  67. Safi, M., WHO platform for pharmaceutical firms unused since pandemic began, in Guardian. 2021,.
  68. WHO. Endorsements of the Solidarity Call to Action. Available from:
  69. Berkley, S. COVAX Explained. 2020; Available from:
  70. A. Acharya, S.G.R., Hoarding is undermining a key effort to vaccinate the Global Poor, in Barron’s,. 2021.
  71. Ghebreyesus, A., T. , Vaccine Nationalism Harms Everyone and Protects No One. Foreign Policy, 2021.
  72. AD, U., A beautiful idea: how COVAX has fallen short. Lancet, 2021. 397(10292): p. 2322-2325.
  73. Turner-Eccleston, M.H.U., International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. The Milbank Quarterly, ,  , 2021. Vol. 99,(No. 2): p. pp. 426-449.
  74. OECD, Coronovirus (COVID-19) vaccines for developing countries: An equal shot at recovery,. 2021. p. 3.
  75. International, O., “Rich Nations Vaccinating one person every second while majority of the poorest nations are yet to give a single dose,. 2021.
  76. Kaplan, T., S.G. Stolberg, R. Robbins accessed Taking extraordinary measures:  Biden backs suspending patents on vaccines,, in The New York Times. 2021.
  77. Campaign, A., EU, UK, Switzerland, Norway must stop blocking negotiations on landmark pandemic monopoly waiver. 2021.
  78. GoC. Procuring Vaccines for COVID-19. 2021 Accessed on 12.01.2021]; Available from:
  79. Access to Information Act, in R.S.C. 1985.
  80. (PMO), P.M.s.O., Prime Minister announces new support for COVID-19 medical research and vaccine development. 2020.
  81. (NRC), N.R.C. About the NRC. 2019 Available from:
  82. (PMO), P.M.s.O., Canada’s Plan to mobilize science to fight Covid-19. 2020: Ottowa, Ontario.
  83. Tumilty, R., Construction Problems prevented National Research Council form Opening vaccine facility on schedule”, in National Post,. 2020.
  84. (PMO), P.M.s.O., New Measures to supply of future vaccines and therapies against COVID-19,. 2020: Montréal, Quebec
  85. (PMO), P.M.s.O., Prime Minister announces funding to advance the development of Canadian COVID-19 vaccine technologies. 2020 Ottawa, Ontario.
  86. Canada, N.R.C., Funding Domestic Vaccine and Therapeutic candidates as part of Government of Canada’s COVID-19 Response. 2020: Montreal Quebec.
  87. ISED, Major investments in domestic firms to rebuild Canada’s biomanufacturing sector. 2021.
  88. CIHR. COVID-19 May 2020 Rapid Research Funding Opportunity Results. 2020 [cited 2023 February 2, ].
  89. CIHR. COVID-19: Tackling Evidence Gaps. 2021 12. 03.2021; Available from:
  90. CIHR, Government of Canada invests in new COVID-19 research projects across the country. 2021.
  91. CIHR. CIHR COVID -19 Investments: By the numbers. 2022 06/06/2022 [cited 2022; Available from:
  92. CIHR. Canadian 2019 Novel Coronavirus (COVID-19) Rapid Research Funding Opportunity Results. 2020; Available from:
  93. GoC, Canadian Network of COVID-19 Clinical Trials Networks. 2021.
  94. Canada, N.S.a.E.R.C.o., College and Community Innovation Program – Applied Research Rapid Response to COVID-19
  1. Innovation, S.a.E.D.I.C. Backgrounder- Government of Canada investments in COVID-19 vaccines, therapeutics, and biomanufacturing capacity,. 2021 February 2, ; Available from:
  2. NRC. Covid 19 response: Building the Infrastructure. 2021; Available from:
  3. Canada, S. Sanofi to build new manufacturing facility in Toronto to strengthen domestic pandemic preparedness and increase global supply  of high-dose  influenza  vaccine,. 2021 March 31, 2021; Available from:
  4. (PMO), P.M.s.O., 2020 New agreements to secure additional vaccine candidates for COVID-19,. 2020: Ottawa, Ontario.
  5. Services, P.S.P. Procuring Vaccines for COVID-19. accessed on 17th of June, 2021]; Available from:
  6. Prime Minister’s Office (PMO) Prime Minister concludes productive G7 Leader’s meeting. 2021: Ottowa, Ontario.
  7. Innovation, S.a.E.D.I.C. COVID-19 Therapeutics Task Force Registry of Interests. 16-12-2020 [cited 2020 December 24th].
  8. Innovation, S.a.E.D.I.C. COVID-19 Vaccine Task Force Registry of Interests. 2022 07-07-2022 [cited 2023 February 11th].
  9. Innovation, S.a.E.D.I.C. COVID-19 Joint Biomanufacturing SubCommittee. 2022 07-07-2022 [cited 2023 February 11].
  10. Lexchin, J., COVID-19 Vaccine Task Force and Conflicts of Interest. Health Policy, 2022. 17(3): p. 20-27.
  11. Canada, N. Declaration of Interests Protocol for the COVID-19 Protocol for the COVID-19 Vaccine Task Force. 2022; Available from:
  12. Services, U.S.D.o.H.a.H. COVID-19 Contracts. Available from:
  13. Curry, B., Liberals lose vote launching COVID-19 study after warning of risks to vaccine negotiations,, in Globe and Mail. 2020.
  14. Pinkerton, C., Feds Criticized for how they disclosed redacted vaccine contracts,. ipolitics 2021.
  15. Wellcome, Sharing Research data and findings relevant to the novel coronavirus (COVID-19) outbreak. 2020
  16. Willinsky, J., “Access Licensing” A COVID-19 Refresh for Compulsory Licensing,. Slaw, 2020.
  17. Lexchin, J., Canada and access to medicines in developing countries: intellectual property rights first. Globalization and Health, 2013. 42(9).
  18. Abbas, Z., A. , Canada’s political choices restrain vaccine equity: the Bolivia-Biolyse Case,. 2021, South Centre,.
  19. ISED. Innovative Solutions Canada Program Challenge Stream – Phase 1 Grant Instructions and Procedures Call 03,. 2020 Modified 5th April 2020, Accessed 1st April 2021,]; Available from:$file/00083_eng.pdf
  20. CIHR. Corono-Virus disease (COVID-19) How was this research funded. 2020 Accessed March 22, 2021]; Available from:,.
  21. CIHR, ATI Response Package 2020.
  22. (SIF), S.I.F., AbCellera COVID 19 Project. 2020.
  23. SIF, VBI Covid 19 Project. 2020.
  24. Moon, S., Adrian Alonso Ruiz, A. Bezruki, S. Agarwal, M. Vieira, S Lessons from Covid-19 Vaccine R&D. , in Submitted to Public Consultation, EU HERA, . 2021.
  25. Moon, S.A.B., G.L. Burci, T. Sunyato, M. Vieria Global Governance of Access to Countermeasures,. 2020.
  26. NRC. Biologics Manufacturing Center. 2021; Available from:
  27. PM Trudeau announces domestic vaccine production deal, provides COVID-19 update-, in Global News. 2021.
  28. GoC, N., Minister Champagne marks the completion of construction of the Biologics Manufacturing Centre in Montréal, . 2021: Montreal,.
  29. Boehm, L.G.P.M., Canada needs a university-based, domestic vaccine- making capability, 2021, Accessed 6th of April 2021 Policy Options, 2021.
  30. News, G., “NDP leader calls for establishing a crown corporation to produce vaccines locally as U.K. approves Pfizer vaccine”. 2020.
  31. ISED, The Government of Canada makes historic investment to strengthen Canada’s biomanufacturing sector. 2021: Toronto, Ontario,.
  32. Herder, M.S.M., A ‘once-in-a-generation’ chance to reset vaccine innovation in Canada,, in Hill Times. 2021.
  33. Herder, M., Biopharmaceuticals, Financialization & Nationalism in the Age of COVID-19. Healthy Debate, 2021.
  34. Nölke, A., Financialization and the Crisis of Democracy, in The Routledge International Handbook of Financialization, D.M. P. Mader, N. van der Zwan, Editor. 2020, Routledge.
  35. Robinson, J.C., Funding of Pharmaceutical Innovation During and After the COVID-19 Pandemic. JAMA, 2021. 325(9): p. 825-826.
  36. Ardizzone K, L.J. Other transaction agreements: government contracts that eliminate protections for the public on pricing, access, and competition, including in connection with COVID-19 vaccines and treatments. KEI Briefing Note No. 2020:3 2020 last updated 2020 Jun 29; Available from: https://www KEI-Briefing-OTA-29june2020.pdf.
  37. International, T., For whose benefit: Transparency in the development and Procurement of COVID 19 Vaccines. 2021.
  38. ISED. Backgrounder- Governmentt of Canada investments in the biomanufacturing, vaccine and therapeutics ecosystem. 2022 30.05.2022; Available from:

Articles in Press, Accepted Manuscript
Available Online from 13 March 2023
  • Receive Date: 11 November 2021
  • Revise Date: 14 February 2023
  • Accept Date: 13 March 2023
  • First Publish Date: 13 March 2023